Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: Nebulised Dexmedetomidine: Patients in Group D will receive nebulised dexmedetomidine 1 mcg/kg (4ml) every 12 hours for the first 72 hours in a semi-recumbent position using a nebulise
Sponsors
DR KESHAVI BHARADWAJ
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients willing to participate 2. Patients of physical status I/II according to American Society of Anaesthesiologists Grading 3. Patients developing PDPH post lower abdominal and lower limb surgeries under spinal anaesthesia within 72 hours 4. Patients qualifying for the criteria of PDPH (with headache severity score more than 4) as laid down by the International Headache Society
Exclusion criteria
Exclusion criteria: 1. Patients having history of allergy to the study drug 2. Patients with body mass index less than 25kg/m2 3. Patient with history of migraine or other types of headache, on chronic treatment of headache 4. Patients with hemodynamic instability or bradyarrythmias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the severity of headache after 24 hours of 1st nebulisationTimepoint: 24 hours post 1st nebulisation | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the incidence rate of PDPH at tertiary care centre, calculate the number of patients requiring additional analgesics, asses any adverse effects (hypotension, bradycardia, oxygen desaturation, dry mouth, sneezing and coughing) during and after nebulisation, compare the analgesic effect of nebulised dexmedetomidine to fentanyl using VAS scoreTimepoint: At 0, 12, 24, 36, 48 and 72 hours of nebulisation | — |
Countries
India
Contacts
Public ContactDR BIBHA KUMARI
Indira Gandhi Institute of Medical Sciences
Outcome results
None listed